Results 1 - 1 of 1
Results 1 - 1 of 1. Search took: 0.019 seconds
[en] Metastatic progression is a common occurrence in patient’s cancer. Published surgical series show that a subset of patients with oligo metastatic disease to the lung or liver will survive for a long time with local treatments only. Data also show that only a minority of patients will present with limited number of metastases, and/or will be deemed suitable for surgical resection because of comorbidities, cumulative toxicity of therapy or anatomical location of the tumors. In primary and oligometastatic setting, stereotactic body radiotherapy (SBRT) has been reported to be an effective alternative therapy. It is minimally invasive, delivers high biological equivalent doses to the target, while minimizing the dose to the critical structures nearby. SBRT is also associated with high rates of local control (70>90%). The reported toxicity is generally low. The overall treatment time for SBRT is significantly shorter than conventional radiotherapy (1-2 weeks for stereotactic body radiotherapy versus 6-8 weeks for conventional radiotherapy). Therefore, this technique is uniquely suitable for patients who are not candidates for other more invasive treatment. The dose per fraction for SBRT is high. Because of this the treatment time for each fraction is long. This requires patient compliance for treatment delivery.